Advertisement

---

GENEREX BIOTECHNOLOGY CORPORATION

Generex Announces Amendment of Form S-1

[2013-07-03] - Clarification in respect of status of Oral Recosulin™ dossier


Generex Announces Conference Call with Members of the Antigen Express Scientific Advisory Board

[2013-07-01] - Conference to feature recent advances in breast cancer immunotherapy and the impact of AE37 and Ii-Key technology


Generex Announces $1,225,000 Capital Investment

[2013-06-17] -


ASCO Interview of MD Anderson's Mittendorf on AE37 Breast Cancer Vaccine Now Available on Generex Websites

[2013-06-13] -


Generex Announces Interview of MD Anderson's Dr. Elizabeth Mittendorf, Principal Investigator on Company's AE37 Phase IIb Breast Cancer Efficacy Trial

[2013-06-12] - Unique abilities of AE37 to activate immune system highlighted


Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients

[2013-06-05] - Treatment Regimen Targets All HER2 Expressing Patients, including those 50% of patients for whom no therapies are available


Positive Generex Data Underscores Cancer Immunotherapy Forecast Issued by Citi

[2013-05-31] - Studies Submitted to ASCO Demonstrate Immunogenic Superiority of AE37 Over All Other Peptide Cancer Vaccines


Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine

[2013-05-22] - Studies show superiority of AE37 among peptide cancer vaccines


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers